The nearly doubled median OS is a strong efficacy signal for gotistobart in a difficult-to-treat indication with limited options. However, this is non-pivotal stage 1 data with a small sample (n=87). Monitor for pivotal stage 2 results and potential regulatory filing updates. The stock may react positively on the data readout, but the binary risk of stage 2 confirmation remains.
Price Chart
Executive Summary
BioNTech and OncoC4 reported updated Phase 3 data for gotistobart in squamous NSCLC, showing median overall survival of 18.5 months vs 10.0 months for chemotherapy (HR 0.56, p=0.0295), nearly doubling survival. The data from stage 1 of the PRESERVE-003 trial is statistically significant but from a non-pivotal stage with only 87 patients, and the pivotal stage 2 is still ongoing. This is a meaningful clinical data update for a pipeline asset, but no revenue or earnings figures are reported, and the filing does not change the company's financial outlook.
Key Facts
- Gotistobart demonstrated median OS of 18.5 months vs 10.0 months for docetaxel (HR 0.56, nominal p=0.0295) in stage 1 of PRESERVE-003 Phase 3 trial
- Data cut-off July 17, 2026 with median follow-up of 25.4 months; 87 patients randomized (45 gotistobart, 42 docetaxel)
- Grade 3 treatment-related AEs: 44.4% gotistobart vs 48.8% docetaxel; safety profile manageable
- Pivotal stage 2 of PRESERVE-003 is ongoing at more than 160 sites globally
- Gotistobart received FDA Fast Track Designation (2022), Orphan Drug Designation (2025), and China NMPA Breakthrough Therapy Designation (2025)
Financial Impact
No financial figures reported; clinical data update only
Risk Factors
- Stage 1 data is non-pivotal with only 87 patients; pivotal stage 2 results could differ
- Competition from other CTLA-4 and immunotherapy approaches in NSCLC
- Regulatory approval is not guaranteed; requires confirmation in larger pivotal trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000063 |
| Document: form6-kwclcgotistobart14se.htm | 0001776985-26-000063 |
| Document: 0001776985-26-000063-index-headers.html | 0001776985-26-000063 |
| Document: 0001776985-26-000063-index.html | 0001776985-26-000063 |
| Document: 0001776985-26-000063.txt | 0001776985-26-000063 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.51 (−2.38%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.51 (−2.38%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.51 (+5.45%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.51 (−12.97%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.51 (+4.00%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.51 (−5.65%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.51 (+4.62%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.51 (+4.62%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.51 (+3.94%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.51 (+12.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access